Radial versus femoral access for percutaneous coronary intervention: implications for vascular complications and bleeding
- PMID: 22733412
- DOI: 10.1007/s11886-012-0287-5
Radial versus femoral access for percutaneous coronary intervention: implications for vascular complications and bleeding
Abstract
Since its advent over two decades ago, transradial access for cardiac catheterization and percutaneous intervention has evolved into a versatile and evidence-based approach for containing the risks of access-site bleeding and vascular complications without compromising the technical range or success associated with contemporary percutaneous coronary intervention (PCI). Early studies demonstrated reduced rates of vascular complications and access-site bleeding with radial-access catheterization but at the cost of increased access-site crossover and reduced procedural success. Contemporary data demonstrate that while the rates of major bleeding with femoral-access PCI in standard-risk cohorts have declined significantly over time, the transradial approach still retains significant advantages by way of reductions in vascular complications, length of stay, and enhanced patient comfort and patient preference over the femoral approach, while maintaining procedural success. Major adverse cardiovascular events and bleeding are lowest with the transradial approach when procedures are performed at high-volume radial centers, by experienced radial operators, or in the context of ST-segment elevation myocardial infarction. Choice of procedural anticoagulation appears to differentially impact access-site bleeding in transradial versus transfemoral PCI; however, non-access site bleeding remains a significant contributor to major bleeding in both groups. Despite abundant supporting data, adoption of transradial technique as the default strategy in cardiac catheterization in the United States has lagged behind many other countries. However, recent trends suggest that interest and adoption of the technique in the United States is growing at a brisker pace than previously observed.
Similar articles
-
Transradial versus transfemoral percutaneous coronary intervention in acute coronary syndromes: re-evaluation of the current body of evidence.JACC Cardiovasc Interv. 2013 Nov;6(11):1149-52. doi: 10.1016/j.jcin.2013.08.003. JACC Cardiovasc Interv. 2013. PMID: 24262614 Review.
-
Transradial and transulnar access for percutaneous coronary interventions.Turk Kardiyol Dern Ars. 2011 Jun;39(4):332-40. doi: 10.5543/tkda.2011.01533. Turk Kardiyol Dern Ars. 2011. PMID: 21646838 Review.
-
Characteristics and Outcomes of Patients With History of CABG Undergoing Cardiac Catheterization Via the Radial Versus Femoral Approach.JACC Cardiovasc Interv. 2021 Apr 26;14(8):907-916. doi: 10.1016/j.jcin.2021.01.053. Epub 2021 Mar 31. JACC Cardiovasc Interv. 2021. PMID: 33812824
-
Costs of transradial percutaneous coronary intervention.JACC Cardiovasc Interv. 2013 Aug;6(8):827-34. doi: 10.1016/j.jcin.2013.04.014. Epub 2013 Jul 17. JACC Cardiovasc Interv. 2013. PMID: 23871512
-
Radial versus femoral access for orally anticoagulated patients.Catheter Cardiovasc Interv. 2010 Oct 1;76(4):493-9. doi: 10.1002/ccd.22527. Catheter Cardiovasc Interv. 2010. PMID: 20882651 Clinical Trial.
Cited by
-
Transradial versus transfemoral rotablation for heavily calcified coronary lesions in contemporary drug-eluting stent era.J Geriatr Cardiol. 2015 Sep;12(5):489-96. doi: 10.11909/j.issn.1671-5411.2015.05.004. J Geriatr Cardiol. 2015. PMID: 26512239 Free PMC article.
-
Outcomes of transradial primary percutaneous intervention from a tertiary cardiac centre in Turkey.Int J Clin Exp Med. 2015 Jul 15;8(7):11404-11. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 26379956 Free PMC article.
-
Ischemic Heart Disease: Special Considerations in Cardio-Oncology.Curr Treat Options Cardiovasc Med. 2017 May;19(5):37. doi: 10.1007/s11936-017-0535-5. Curr Treat Options Cardiovasc Med. 2017. PMID: 28425056 Review.
-
Coronary Artery Disease and Cancer: Treatment and Prognosis Regarding Gender Differences.Cancers (Basel). 2022 Jan 16;14(2):434. doi: 10.3390/cancers14020434. Cancers (Basel). 2022. PMID: 35053596 Free PMC article. Review.
-
Integrin αIIbβ3 outside-in signaling.Blood. 2017 Oct 5;130(14):1607-1619. doi: 10.1182/blood-2017-03-773614. Epub 2017 Aug 9. Blood. 2017. PMID: 28794070 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous